Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FANTASTIC: mFOLFOXIRI vs mFOLFOX6 in Locally Advanced Colorectal Cancer
NCT04338191Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2020
- Primary completion
- Feb 2025
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Started Apr 2020; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04338191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338191.